ALVO Alvotech

$ALVO Alvotech initiated with a Buy at Jefferies ALVO , TEVA | 6:24 AM Jefferies initiated coverage of Alvotech (ALVO) with a Buy rating and $9 price target. U.S. biosimilars Humira and Stelara are growing steadily due to partner Teva's (TEVA) solid execution, says the analyst, who sees revenue and EBITDA growth over the next five years based on two products approved in the U.S., three more by year-end and multiple outside of U.S. launches in various markets

$ALVO I think the upcoming Q3 numbers will be mostly irrelevant, as the major revenue boost is expected for Q4. It will be key for us, if $ALVO keeps the outlook for 2026, which I hope. Much more relevant will be the FDA approval for AVT03, AVT05 and AVT06, which hopefully will be announced no later than early December. And also the outcome of the current IP litigation regarding the Simponi biosimilar (AVT05), with a decision expected in the coming weeks as well. An adverse ruling could delay the U.S. launch of AVT05, impacting a key 2027 growth pillar. Some really good news already hit the wire recently: The October 2026 FDA approval of an additional manufacturing suite (DSM2) at its Reykjavik facility effectively doubles drug substance capacity for the U.S. market. Simultaneously, a new manufacturing process for SIMLANDI more than doubles output per batch. So from a manufacturing standpoint the upcoming US launches seem very well prepared.

Top watches today $ALVO ~$5 / fresh FDA manufacturing approval doubles SIMLANDI output / prior $3 75 financing is the dilution flag $CRMD ~$7 38 / REZZAYO priority review accepted / FDA decision Q1 2027 / convertible debt risk $RIG ~$5 89 / $550M in new drilling backlog / heavy debt remains $CLF ~$14 10 / strong earnings and improved outlook / watch a pullback after the run $FSM ~$10 59 / fresh gold drilling results / secondary watch <@&997794587307425934>

$ALVO I mentioned previously that I sold out of a very large position above $6.10 for close to a double and planned to wait until $4.50 to buy back in, a price I honestly thought we might never see. Well, here we are. Why is buying back into a stock you are completely out of always so much harder mentally than selling it? I might regret this, but I'm going to give it a little more room and see if it tests the 200-day moving average and $4.10 or chase on a turn. Fundamentals for 2027+ are great and just trying to time the best prices.

$ALVO Extrapolating Alvotech's 2026 projected revenue into 2027 yields $832.1 million using its annual growth trajectory, which aligns closely with the Wall Street consensus estimate of $785.9 million, easily justifying a PPS of $10+ due to the further accelerating growth story.

$ALVO Alvotech's implied fourth-quarter revenue is well beyond $300 million, projecting between $326.6 million and $376.6 million to meet its full-year 2026 guidance. The most realistic implied target for Q4 sits near $326.6 million at the lower end - however it will be a blowout quarter.

$ALVO Biosimilar maker Alvotech filed AVT29, its copy of the Eylea 8 mg eye drug, with EU regulators; the 8 mg dose was ~57% of global Eylea 2mg+8mg sales in Q2 2026, up from ~30% a year earlier, per the release. Market value ~$1.96B at $5.51 Oct 12, 2026 close: 312.0M shares at Dec 31, 2025 (~$1.72B) plus 43.9M sold in June 2026 at $3.75. Still only a filing: no review timeline or milestone payment given, and partner Advanz Pharma sells in Europe while Alvotech supplies. Next: EMA review; FDA decisions on the 2 mg version, AVT06, expected in Q4 2026.

$ALVO this company has a monster pipeline. The patent cliff will carve a massive hole for Alvotech to take on and print some serious revenue...this is a buy and accumulate eventually in 10 years we might get to see a seriously interesting return...

$ALVO Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.24 down -700.00% YoY • Reported revenue of $111.6M down -2.02% YoY • Alvotech maintains full-year 2026 guidance for total revenue of $650M and EBITDA of $180M, with performance now expected toward the lower end of the range.

$ALVO is not a trial readout and it still matters FDA cleared Process 2.0 for SIMLANDI this morning. More than double the drug substance per batch, same upstream scale closed Monday at $5.03, trading $5.38 premarket, up about 7 percent. same plant, fewer batches, capacity left over for the rest of the portfolio imo